

Corporate Credit Rating

⊠New □Update


Sector: Healthcare Services Publishing Date: 28/02/2024 Senior Analyst Ezgi Çiçek YILMAZ +90 212 352 56 73

ezgi.yilmaz@jcrer.com.tr

Assistant Analyst Seyma ARSLAN +90 212 352 56 73

seyma.arslan@jcrer.com.tr

RATINGS		Long Term	Short Term
ICRs (Issuer Credit Rating Profile)	National ICR	A- (tr)	J2 (tr)
	National ICR Outlooks	Stable	Stable
	International FC ICR	BB	-
	International FC ICR Outlooks	Negative	-
	International LC ICR	BB	
	International LC ICR Outlooks	Negative	-
ISRs (Issue Specific Rating Profile)	National ISR	-	-
	International FC ISR	-	
	International LC ISR	-	-
Sovereign*	Foreign Currency	BB (Negative)	-
	Local Currency	BB (Negative)	-
* Assigned by JCR on Aug 18, 2022			



LOKMAN HEKİM ENGÜRÜSAĞ SAĞLIK TURİZM EĞİTİM HİZMETLERİ VE İNŞAAT TAAHHÜT A.Ş.

JCR Eurasia Rating has evaluated the consolidated structure of "Lokman Hekim Engürüsağ Sağlık Turizm Eğitim Hizmetleri ve İnşaat Taahhüt A.Ş." in the high investment level category, assigned the Long-Term National Issuer Credit Rating as 'A- (tr)' and the Short-Term National Issuer Credit Rating as 'J2 (tr)' with 'Stable' outlooks. On the other hand, the Long-Term International Foreign and Local Currency Issuer Credit Ratings and outlooks were determined as 'BB/Negative' in line with the sovereign ratings and outlooks of Republic of Türkiye.

"Lokman Hekim Engürüsağ Sağlık Turizm Eğitim Hizmetleri ve İnşaat Taahhüt A.Ş." (hereinafter referred to as "Lokman Hekim" or "the Group" or "the Company") was established in 1996 in Ankara, Türkiye. The Group operates in the healthcare sector with 6 hospitals, 2 medical centres, fully equipped laboratories and advanced medical units.

Lokman Hekim has 7 subsidiaries and has a total of 2,208 employees as of 3Q2023 (FYE2022: 2,342).

As of 3Q2023, 71.67% of shares are publicly traded on the Borsa Istanbul (BIST) with the ticker symbol "LKMNH".

Key rating drivers, as strengths and constraints, are provided below.

Strengths	Constraints	
 Consistent sales revenue and EBITDA generation capacity in FY2022 and expected to continue in 2023 financials, Reasonable net debt to EBITDA multiplier in the analyzed periods, Positive cash flow metrics in the analyzed periods despite free operating cash outflow in FY2022 due to CapEx, Satisfactory equity level supported by internal resource generation capacity in the analyzed periods despite increasing dividend pay-out ratio limiting equity growth, High level of compliance regarding corporate governance implementations, Long-lasting presence in the sector dating back to 1996 and brand awareness together with participation in the Turguality programme. 	 Net working capital deficit compelling liquidity management in the analyzed periods, Low level of paid-in capital in comparison to the asset size, Increasing costs in the healthcare sector suppressing the profitability of the Group, Intense competition in the sector, Leading economic indicators signal global economic slowdown whereas quantitative tightening actions aim to restrict consumption growth and achieve a soft- landing in the domestic side. 	

Considering the aforementioned points, the Group's Long-Term National Issuer Credit Rating has been assigned as 'A- (tr)'. The Group's consistent sales revenue and EBITDA generation capacity, reasonable level of net debt to EBITDA multiplier, satisfactory equity level as well ongoing net working capital deficit, low level of paid-in capital and slowdown signal in the global economy have been evaluated as important indicators for the stability of the ratings and the outlooks for Long and Short-Term National Issuer Credit Ratings are determined as 'Stable'. The Group's financial structure, sales and profitability performance, continuity of EBITDA generation capacity and debt structure will be closely monitored by JCR Eurasia Rating in the upcoming periods. The macroeconomic indicators at national and international markets, as well as market conditions and legal framework about the sector will be monitored as well.

Copyright © 2007 by JCR Eurasia Rating. Maslak Mahallesi Taşyoncası Sokak No:1/F F2 Blok Kat:2 34485 Sarıyer/İstanbul/Türkiye Telephone: +90(212)352.56.73 Fax: +90 (212) 352.56.75 Reproduction is prohibited except by permission. All rights reserved. All information has been obtained from sources JCR Eurasia Rating believes to be reliable and information/clarifications provided by the Company. However, JCR Eurasia Rating does not guarantee the truth, accuracy and adequacy of this information. JCR Eurasia Rating ratings are objective and independent opinions as to the creditworthiness of a security and issuer and not to be considered a recommendation to buy, hold or sell any security or to issue a loan. This rating report has been composed within the methodologies registered with and certified by the SPK (CMB-Capital Markets Board of Türkiye), BDDK (BRSA-Banking Regulation and Supervision Agency) and internationally accepted rating principles and guidelines but is not covered by NRSRO regulations. http://www.jcrer.com.tr